PCRX Earnings Prediction
The chart below shows how PCRX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, PCRX sees a +2.10% change in stock price 10 days leading up to the earnings, and a -5.96% change 10 days following the report. On the earnings day itself, the stock moves by -0.80%. This data can give you a slight idea of what to expect for the next quarter's release.
PCRX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
168.57M
2.83%
-5.31%
Gross Margin
68.45%
2.15%
2.03%
Operating Margin
13.02%
1.24%
-25.17%
Net Margin
-85.11%
-1385.65%
-902.17%
EPS
-3.11
-1452.17%
-897.44%
No Data Available
PCRX Earnings Analysis
Pacira BioSciences, Inc. Common Stock Corporation (PCRX.O) Earnings Conference Call
Positive
EXPAREL Sales Increase: Third quarter EXPAREL sales increased to $132 million versus $128.7 million in 2023.
ZILRETTA Sales Stability: Third quarter ZILRETTA sales of $28.4 million were essentially flat versus the $28.8 million reported in 2023.
Sales Increase: For iovera*, sales were $5.7 million compared to $5.3 million in the third quarter of 2023.
Strong Gross Margin Performance: On a consolidated basis, our third quarter non-GAAP gross margin was 78%, driven by strong margins for all three products.
Strong Cash Position: We exited the third quarter in a position of strength with more than $450 million of cash and investments.
Negative
ZILRETTA Sales Stability: Third quarter ZILRETTA sales of $28.4 million were essentially flat versus the $28.8 million reported in 2023.
Sales Increase: For iovera, sales were $5.7 million compared to $5.3 million in the third quarter of 2023.
Strong Gross Margin Performance: On a consolidated basis, our third quarter non-GAAP gross margin was 78%, this was driven by strong margins for all three products.
R&D Expense Decrease: For non-GAAP R&D expense, the third quarter decreased to $17.3 million from $18.6 million reported last year.
Cost Decline Factors: This decrease relates to declines in product development and manufacturing capacity expansion costs, as well as regulatory expenses.
PCRX FAQs
How does PCRX typically perform around its earnings report dates?
Is Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
PCRX Earning Call Sentiment
Pacira Biosciences Inc. (PCRX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
PCRX.O
0%Positive
The earnings call reveals mixed signals: strong financials with a positive cash position, but concerns over patent litigation and competitive pressures. While EXPAREL sales show growth, ZILRETTA remains flat. The Q&A highlights management's optimism but also their vague responses on key issues like NOPAIN implementation and generic competition. The lack of a specific shareholder return plan and potential supply chain issues further temper positive sentiment. Overall, the stock is likely to remain neutral, with no strong catalysts for significant movement either way.
